These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches. Yoon HR; Balupuri A; Choi KE; Kang NS Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation. Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072 [TBL] [Abstract][Full Text] [Related]
5. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations. Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584 [TBL] [Abstract][Full Text] [Related]
6. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity. Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319 [TBL] [Abstract][Full Text] [Related]
7. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification. Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116 [TBL] [Abstract][Full Text] [Related]
8. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors. Pan Y; Wang Y; Bryant SH J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085 [TBL] [Abstract][Full Text] [Related]
9. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design. Meine R; Becker W; Falke H; Preu L; Loaëc N; Meijer L; Kunick C Molecules; 2018 Jan; 23(2):. PubMed ID: 29364148 [TBL] [Abstract][Full Text] [Related]
10. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis. Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399 [TBL] [Abstract][Full Text] [Related]
11. Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules. Rothweiler U; Stensen W; Brandsdal BO; Isaksson J; Leeson FA; Engh RA; Svendsen JS J Med Chem; 2016 Nov; 59(21):9814-9824. PubMed ID: 27736065 [TBL] [Abstract][Full Text] [Related]
12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease. Iqbal S; Anantha Krishnan D; Gunasekaran K J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053 [TBL] [Abstract][Full Text] [Related]
14. How to design potent and selective DYRK1B inhibitors? Molecular modeling study. Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861 [TBL] [Abstract][Full Text] [Related]
15. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives. Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214 [TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors. Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133 [TBL] [Abstract][Full Text] [Related]
17. Identification of potential PIM-2 inhibitors via ligand-based generative models, molecular docking and molecular dynamics simulations. Qin T; Wang Y; Kong M; Zhong H; Wu T; Xi Z; Qian Z; Li K; Cai Y; Wu J; Li W Mol Divers; 2024 Aug; 28(4):2245-2262. PubMed ID: 38954072 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors. Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883 [TBL] [Abstract][Full Text] [Related]
19. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262 [TBL] [Abstract][Full Text] [Related]